Halozyme Therapeutics To Participate In Upcoming Healthcare Conferences

Share This

05/29/2018

SAN DIEGO, May 29, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will participate in two upcoming investor conferences.

Dr. Helen Torley, president and chief executive officer will represent Halozyme in a question and answer session at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes on Tuesday, June 12 at 6:20 p.m. ET / 3:20 p.m. PT.

On Wednesday, June 20, Laurie Stelzer, senior vice president and chief financial officer will represent Halozyme in a question and answer session at the 2018 JMP Securities Life Sciences Conference in New York at 2:30 p.m. ET / 11:30 a.m. PT.

Webcasts of both sessions can be accessed through the "Investors" section of www.halozyme.com, and a recording will be made available for 90 days following each event. To access a live webcast, please visit Halozyme's website approximately 15 minutes prior to the presentation to register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug pegvorhyaluronidase alfa (PEGPH20), applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb and Alexion for its ENHANZE® drug delivery technology. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

Contacts:
Jim Mazzola
858-704-8122
ir@halozyme.com

Chris Burton
858-704-8352
ir@halozyme.com

Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/halozyme-therapeutics-to-participate-in-upcoming-healthcare-conferences-300655885.html

SOURCE Halozyme Therapeutics, Inc.

Notice

You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.

Ok